321
Views
9
CrossRef citations to date
0
Altmetric
Drug Discovery Case History

Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma

, &

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Mostafa M. Ghorab, Mansour S. Alsaid, Aiten M. Soliman & Fatma A. Ragab. (2017) VEGFR-2 inhibitors and apoptosis inducers: synthesis and molecular design of new benzo[g]quinazolin bearing benzenesulfonamide moiety. Journal of Enzyme Inhibition and Medicinal Chemistry 32:1, pages 893-907.
Read now

Articles from other publishers (8)

Lian Liu, Xiaoxue Li, Qian Zhao, Lihua Yang & Xian Jiang. (2022) Pathogenesis of Port-Wine Stains: Directions for Future Therapies. International Journal of Molecular Sciences 23:20, pages 12139.
Crossref
Eman Z. Elrazaz, Rabah A.T. Serya, Nasser S.M. Ismail, Amgad Albohy, Dalal A. Abou El Ella & Khaled A.M. Abouzid. (2021) Discovery of potent thieno[2,3-d]pyrimidine VEGFR-2 inhibitors: Design, synthesis and enzyme inhibitory evaluation supported by molecular dynamics simulations. Bioorganic Chemistry 113, pages 105019.
Crossref
Mohd. Imran, Syed Mohammed Basheeruddin Asdaq, Shah Alam Khan, Dhanalekshmi Unnikrishnan Meenakshi, Abdulhakeem S. Alamri, Walaa F. Alsanie, Majid Alhomrani, Yahya Mohzari, Ahmed Alrashed, Mohammed AlMotairi, Eman H. Alkhaldi, Abeer K. Alorabi, Ahmed Subeh Alshrari, Mohammad Tauseef, Abida, Saleh I. Alaqel, Ozair Alam & Md. Afroz Bakht. (2021) Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades. Pharmaceuticals 14:8, pages 710.
Crossref
Timothy P. Heffron. (2016) Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer. Journal of Medicinal Chemistry 59:22, pages 10030-10066.
Crossref
Jennifer J. Wheler, Filip Janku, Aung Naing, Yali Li, Bettzy Stephen, Ralph Zinner, Vivek Subbiah, Siqing Fu, Daniel Karp, Gerald S. Falchook, Apostolia M. Tsimberidou, Sarina Piha-Paul, Roosevelt Anderson, Danxia Ke, Vincent Miller, Roman Yelensky, J. Jack Lee, David Hong & Razelle Kurzrock. (2016) TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics . Molecular Cancer Therapeutics 15:10, pages 2475-2485.
Crossref
Yoshinori Takeuchi & Makoto Bonkobara. (2016) Receptor tyrosine kinase KIT: Prognostic and therapeutic involvement in canine mast cell tumours. The Veterinary Journal 210, pages 5-6.
Crossref
Leilei Shi, Jianfeng Zhou, Jifeng Wu, Junya Cao, Yuemao Shen, Hua Zhou & Xun Li. (2016) Quinoxalinone (Part II). Discovery of (Z)-3-(2-(pyridin-4-yl)vinyl)quinoxalinone derivates as potent VEGFR-2 kinase inhibitors. Bioorganic & Medicinal Chemistry 24:8, pages 1840-1852.
Crossref
Meng Michelle Xu, Yang Pu, Yuan Zhang & Yang-Xin Fu. (2016) The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies. Trends in Immunology 37:2, pages 141-153.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.